Predicting Medication Response in Obsessive Compulsive Disorder

Obsessive Compulsive Disorder Clinical Trial

Official title:

Predicting Medication Response in Obsessive Compulsive Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01404871
• Other study ID #: OCF-Richter
• Status: Completed
• Phase: N/A
• First received: February 6, 2009
• Last updated: January 30, 2013
• Start date: April 2009
• Est. completion date: December 2011

Study information

• Verified date: January 2013
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

In this study, the investigators hope to study a number of variables the investigators believe may help us predict why some people respond better to some medications than others. Participants will be randomly assigned to receive one of two typical medications for OCD, clomipramine or escitalopram. Individuals who would like to participate but who have previously tried one or both of these medications may instead take a newer drug, duloxetine, and undergo the identical procedures. The factors the investigators will be studying include demographics (i.e. age, gender, age of onset of OCD), genetic markers (such as variants in genes involved in breaking down drugs in the liver (cytochrome P450 system), and genes involved in several brain chemical systems, such as serotonin), the dimensions of OCD symptoms (i.e. checking, washing, and hoarding) and cortical inhibition. Cortical inhibition will be measured transcranial magnetic stimulation and is being studied because deficits in this process may be important in the development of OCD. The investigators hypothesize that certain pretreatment clinical characteristics will correlate with poor treatment response including earlier age of onset, longer duration of illness, increased YBOCS severity and presence of significant hoarding symptoms. The investigators expect that increasing degree of deficit in CI pre-treatment will predict poor treatment response, but that increase in CI from pre- to post-treatment will correlate with a positive treatment response. Differences in genetic marker status for cytochrome P450 genes will correlate with tolerability and/or response, as well as differences in genetic marker status in SLC1A1, GRIN2B, 5HT1B and 5HT2A will correlate with response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: December 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of Obsessive Compulsive Disorder

• Must be able to swallow tablets

Exclusion Criteria:

• History of stroke

• History of Parkinson's disease

• History of Epilepsy

• Clinical diagnosis of Schizophrenia or schizoaffective disorder

• Clinical diagnosis of Bipolar Affective disorder

• Active suicidality

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)

Related Conditions & MeSH terms

• Compulsive Behavior
• Obsessive Compulsive Disorder
• Obsessive-Compulsive Disorder

Intervention

Drug:
• clomipramine
oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily
• escitalopram
oral tablet, starting 10mg/daily 12 week treatment including >8 weeks at max dose 50mg daily
• duloxetine
oral tablets, starting dose 30mg daily 12 week treatment including >8weeks at 120mg daily

Locations

Country	Name	City	State
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	The Centre for Addiction and Mental Health	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre	Centre for Addiction and Mental Health, Obsessive Compulsive Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	YBOCS Obsessive-Compulsive Severity Score	The YBOCS yields an OCD severity score by scoring participants on time, interference, distress, resistance and control of their obsessive and compulsive symptoms on a scale of 0-4. When these scores are summed, they give a total severity score from 0-40. The primary outcome will measure the degree of change in this measurement from pre- to post-treatment.	Bi-monthly (every 2 weeks for duration of trial. Approx. 12 weeks)	No
Primary	Clinical Global Improvement - Improvement Scale	This is a clinician/Research assistant rated score of clinical improvement. Both treating physician and research assistant (who interviews the participant every two weeks) will independently provide ratings from 1-7, 1 being very much improved and 7 being very much worse.	Bi-monthly (every 2 weeks for duration of trial. Approx. 12 weeks)	No
Secondary	Change in cortical Inhibition (CI) as measured with Transcranial Magnetic Stimulation.		Pre- and post-treatment (typically, 0 weeks and 12 weeks)	No
Secondary	Genotype marker data for SLC1A1, GRIN2B, 5HT1B, 5HT2A and P450 enzymes CYP2D6 and CYP2C19.	We will initially focus on GLU and GABA gene candidates for which there is good evidence of involvement in cortical inhibition. We will also prioritize other markers previously implicated in response and/or etiology of the illness including 5HT1B, 5HT2A, 5HTT, DRD3, DRD4, MOG, BDNF, MAOA, COMT. We will test 200 SNPs across these 12 genes, and also explore any highly promising genes emerging from the literature as time and resources permit. We will test both single markers and haplotypes. Genotyping of CYP2D6 and CYP2C19 will be typed by the Roche Diagnostics Amplichip (www.amplichip.us).	Collected at week 0, analyzed periodically (approx. 1x/year)	No
Secondary	Tolerability/side effects measure with Udvalg for Liniske Undersogelser Side Effect Rating Scale (UKU).		Bi-monthly (every 2 weeks for duration of trial. Approx. 12 weeks)	Yes
Secondary	Clinical Global Impression - Severity Scale.		Bi-monthly (every 2 weeks for duration of trial. Approx. 12 weeks)	No
Secondary	Depression symptoms will be rated with the Beck Depression Inventory (BDI).		Bi-monthly (every 2 weeks for duration of trial. Approx. 12 weeks)	No
Secondary	DYBOCS (Dimensional Yale-Brown Obsessive-Compulsive Scale)		start, middle and end of trial (typically, 0, 6 and 12 weeks)	No